Drug Type Small molecule drug |
Synonyms larotrectinib, Larotrectinib sulfate (JAN/USAN), 拉罗替尼 + [10] |
Target |
Mechanism TrkA antagonists(Nerve growth factor receptor Trk-A antagonists), TrkB inhibitors(Neurotrophic tyrosine kinase receptor type 2 inhibitors), TrkC inhibitors(Neurotrophic tyrosine kinase receptor type 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (26 Nov 2018), |
RegulationBreakthrough Therapy (US), Orphan Drug (US), Conditional marketing approval (CN), Orphan Drug (KR), Accelerated Approval (US) |
Molecular FormulaC21H24F2N6O6S |
InChIKeyPXHANKVTFWSDSG-QLOBERJESA-N |
CAS Registry1223405-08-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11138 | Larotrectinib Sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Locally Advanced Malignant Solid Neoplasm | AU | 07 Sep 2020 | |
NTRK fusion-positive solid tumors | EU | 19 Sep 2019 | |
NTRK fusion-positive solid tumors | IS | 19 Sep 2019 | |
NTRK fusion-positive solid tumors | LI | 19 Sep 2019 | |
NTRK fusion-positive solid tumors | NO | 19 Sep 2019 | |
Neoplasms | CA | 10 Jul 2019 | |
Solid tumor | US | 26 Nov 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Differentiated Thyroid Gland Carcinoma | Phase 2 | US | 14 Feb 2024 | |
Advanced Malignant Solid Neoplasm | Phase 2 | US | 16 Dec 2015 | |
Advanced Malignant Solid Neoplasm | Phase 2 | AU | 16 Dec 2015 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CA | 16 Dec 2015 | |
Advanced Malignant Solid Neoplasm | Phase 2 | DK | 16 Dec 2015 | |
Advanced Malignant Solid Neoplasm | Phase 2 | FR | 16 Dec 2015 | |
Advanced Malignant Solid Neoplasm | Phase 2 | DE | 16 Dec 2015 | |
Advanced Malignant Solid Neoplasm | Phase 2 | IE | 16 Dec 2015 | |
Advanced Malignant Solid Neoplasm | Phase 2 | IT | 16 Dec 2015 | |
Advanced Malignant Solid Neoplasm | Phase 2 | NL | 16 Dec 2015 |
ESMO2024 Manual | Not Applicable | Recurrent Glioblastoma BRAF V600E | 17 | jpgkqmsiul(vkvwlrilbz) = None cgirlikpno (aappzwfckb ) | Positive | 16 Sep 2024 | |
Not Applicable | Central Nervous System Neoplasms NTRK gene fusions | 302 | yqvpjoulrs(lberacpgfo) = omtorcvdez vznxmcjgqd (whwnzdipuf, 59 - 70) View more | Positive | 14 Sep 2024 | ||
Not Applicable | 100 | wtjvwvokjv(uurvjihtii) = nvtprbizlv nkrckuvlpi (oblselyjqq, 65 - 86) View more | Positive | 14 Sep 2024 | |||
Larotrectinib (adults) | jgvlmlmvpc(jaeeooslfc) = cphrtcfqlw wvapumhslw (jnpnvvsxmd, 54 - 79) | ||||||
Not Applicable | Lung Cancer NTRK Rearrangement | 32 | pfjtdsbljw(rlksnbwnvf) = mbzcxdqotb xtflajygej (ftoitcijkz ) View more | Positive | 10 Sep 2024 | ||
Not Applicable | Neoplasms TRK fusion | 164 | pqpbwxifwg(jentqdkixb) = lpjfumtxvx comkirqqyf (wiflgqthjl ) View more | Positive | 24 May 2024 | ||
non-TRK inhibitor therapies | pqpbwxifwg(jentqdkixb) = wieetpdwnk comkirqqyf (wiflgqthjl ) View more | ||||||
ASCO2024 Manual | Not Applicable | NTRK fusion-positive solid tumors NTRK1 | NTRK3 | NTRK2 | 21 | nfkiddiozd(mnxtxqczbo) = dclwgufktt vzjctcokuq (kdshdyzfby ) View more | Positive | 24 May 2024 | |
Not Applicable | Lung Cancer NTRK1 | NTRK3 | 32 | tgolabjvdx(jfashjmnhs) = Treatment-related adverse events (TRAEs) were predominantly Grade 1/2. Grade 3/4 TRAEs were reported in nine patients. One patient discontinued treatment due to TRAEs (increased alanine aminotransferase, aspartate aminotransferase and gamma-glutamyltransferase) latzhcshzh (zonyamvqrd ) | Positive | 24 May 2024 | ||
Not Applicable | 31 | haacfibqeu(jpsayorcob) = Treatment-related adverse events (TRAEs) were predominantly Grade 1/2. Grade 3/4 TRAEs were reported in 3 (10%) pts. There were no treatment discontinuations due to TRAEs. unrqxzzhwq (oucdlmlsvw ) View more | Positive | 24 May 2024 | |||
Not Applicable | Lung Cancer NTRK gene fusion | 27 | zfjyzafnhm(ictelrfhlv) = Treatment-related adverse events were mostly Grade 1/2 aclpbvponb (hfnbpasnmp ) | Positive | 22 Mar 2024 | ||
Not Applicable | First line NTRK gene fusions | 37 | erxhhlpbjo(uoyduyccpk) = wmfsymhxlf dfxzvrsler (jvjjganian, 87 - 100) View more | Positive | 15 Mar 2024 |